Advertisement

Topics

Protiva Biotherapeutics Company Profile

02:26 EDT 22nd September 2017 | BioPortfolio

Drug development using non-viral lipid-mediated gene delivery.

Location

150 - 8900 Glenlyon Parkway
Burnaby
British Columbia
V5J 5J8
Canada


News Articles [169 Associated News Articles listed on BioPortfolio]

Lion Biotechnologies changes name to Iovance Biotherapeutics

Iovance Biotherapeutics, a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, changed its corporate name from Lion Biotechnologies t...

Pfizer starts work on Missouri biotherapeutics R&D hub

Pfizer is building a $200m (€179m) R&D centre in Chesterfield, Missouri at which it will consolidate biotherapeutics process development operations in the region.

Iovance Biotherapeutics appoints Timothy Morris CFO

Iovance Biotherapeutics, a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, announced the appointment of Timothy E. Morris as Chie...

Pierre Fabre Acquires Immunotherapies from Igenica Biotherapeutics

NewsPierre Fabre Pharmaceuticals acquires promising assets from Igenica Biotherapeutics in the field of immuno-oncology.

Agilis Biotherapeutics, Gene Therapy Research Institution partner

Agilis Biotherapeutics, a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), and Gene Therapy Research Institution (GTR...

Biotech Aeglea BioTherapeutics nets $11.7mm through FOPO

Aeglea BioTherapeutics Inc. (enzyme-based therapeutics for rare diseases and cancer) netted $11.7mm through a follow-on public offering of 3mm common shares at $4.10. The company will use the offerin...

Pierre Fabre to buy Igenica Biotherapeutics’ assets for treating cancer patients

French private pharmaceutical group Pierre Fabre has signed a new definitive purchase agreement to acquire several assets from US biotechnology company Igenica Biotherapeutics.

Eleven Biotherapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

Tuesday, September 5th 2017 at 12:00pm UTC CAMBRIDGE, Mass.–(BUSINESS WIRE)– Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline o...

Drugs and Medications [14 Associated Drugs and Medications listed on BioPortfolio]

Plasmanate [TALECRIS BIOTHERAPEUTICS, INC.]

Plasma Protein Fraction (Human) 5%, USPPlasmanate®

Gamastan s/d [TALECRIS BIOTHERAPEUTICS, INC.]

Immune Globulin (Human)GamaSTAN™ S/DSolvent/Detergent Treated

Plasbumin [TALECRIS BIOTHERAPEUTICS, INC.]

Albumin (Human) 5%, USPPlasbumin ®-5

Plasbumin [TALECRIS BIOTHERAPEUTICS, INC.]

Albumin (Human) 5%, USPPlasbumin ®-5

Plasbumin [TALECRIS BIOTHERAPEUTICS, INC.]

Albumin (Human) 20%, USPPlasbumin®-20

PubMed Articles [14 Associated PubMed Articles listed on BioPortfolio]

TILT Biotherapeutics.

Peptide dendrons as thermal stability amplifiers for IgG1 monoclonal antibody biotherapeutics.

Biotherapeutics such as monoclonal antibodies (mAbs) have a major share of the pharmaceutical industry for treatment of life-threatening chronic diseases such as cancer, skin ailments and immune disor...

Recommendations for Systematic Statistical Computation of Immunogenicity Cut Points.

Today, the assessment of immunogenicity is integral in nonclinical and clinical testing of new biotherapeutics and biosimilars. A key component in the risk-based evaluation of immunogenicity involves ...

To engraft or not to engraft: an ecological framework for gut microbiome modulation with live microbes.

Strategies aimed at modulating the gut microbiota by using live microbes range from single strains (probiotics or live biotherapeutics) to whole non-defined fecal transplants. Although often clinicall...

Using transgenic plants and modified plant viruses for the development of treatments for human diseases.

Production of proteins in plants for human health applications has become an attractive strategy attributed by their potentials for low-cost production, increased safety due to the lack of human or an...

Clinical Trials [4 Associated Clinical Trials listed on BioPortfolio]

Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)

The purpose of this study is to: - evaluate the safety profile of a single intravenous administration of AIGIV (containing either 3.5 mg/kg, 7.0 mg/kg or 14.0 mg/kg anti-PA IgG) a...

A Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Injections of Elamipretide (MTP-131) in Subjects With Genetically Confirmed Mitochondrial Disease Previously Treated in the Stealth BioTherapeutics SPIMM-201 Study

This is a Phase 2, randomized, double-blind, placebo-controlled crossover study which will enroll up to 36 subjects (anticipated) with genetically confirmed mitochondrial disease who have ...

The Effect of OASIS Ultra on Critical Sized Wound Healing

The aim of this study is to evaluate the speed and quality with which OASIS® Ultra (Healthpoint Biotherapeutics; Fort Worth, Texas) increases wound healing in the critical sized defect. ...

Personalized Immunotherapeutics for Antibiotic-resistant Infection

M. A. suffers from hypogammaglobulinemia that has been complicated by refractory Mycoplasma hominis septic arthritis. He has been receiving the antibiotic valnemulin under Emergency Invest...

Companies [94 Associated Companies listed on BioPortfolio]

Protiva Biotherapeutics INC

Protiva is a development stage biotechnology company, focused on pharmaceutical products to fight serious human disease. Protiva's proprietary SNALP technology enables the development of novel nucleic...

Protiva Biotherapeutics

Drug development using non-viral lipid-mediated gene delivery.

Aevum Life Science

Aevum Life Science ™ was founded in 2010, to develop the highest quality, clinically focused products, to help women during pregnancy and while recovering and breast...

Axial Biotherapeutics

Axial Biotherapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and the central nervous system to develop a new class of biotherapeutics ...

Napro Biotherapeutics Incorporated

NaPro BioTherapeutics, Inc. is a natural product pharmaceutical company focused primarily on the development, manufacture and commercializa tion of paclitaxel, a naturally-occurring anti-cancer agent ...

More Information about "Protiva Biotherapeutics" on BioPortfolio

We have published hundreds of Protiva Biotherapeutics news stories on BioPortfolio along with dozens of Protiva Biotherapeutics Clinical Trials and PubMed Articles about Protiva Biotherapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Protiva Biotherapeutics Companies in our database. You can also find out about relevant Protiva Biotherapeutics Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...


Corporate Database Quicklinks



Searches Linking to this Company Record